Point-of-Care Antimicrobial Susceptibility Testing After the Longitude Prize | Diagnostics Market Intelligence

Description

List of Tables

In 2024 the Longitude Prize - an eight-million-pound challenge to build a rapid, accurate, point-of-care antibiotic susceptibility test - was awarded to PA-100, a microfluidic phenotypic system developed by Astrego and now owned by Sysmex. The prize was designed to reward a specific clinical proposition: that a fifteen-minute answer to which antibiotic will work could change prescribing at the moment it happens, rather than days later. The award validated the technology. It did not decide whether health systems will pay for it, and that question is where the real contest now sits.

The unresolved issues form a chain. Evidence: regulators and HTA bodies want proof that faster susceptibility results change antibiotic use and patient outcomes, not just turnaround times, and that evidence is still being generated. Economics: the target setting - community prescribing for urinary tract infections - is a high-volume, low-price environment where even a modest per-test cost must justify itself against empiric prescribing that costs almost nothing. Regulation: Europe's IVDR reclassification is raising the bar and the cost of staying on the market, while Japan's PMDA pathway for phenotypic AST is largely untested at the point of care. Competition: the incumbent laboratory AST suppliers are not standing still, and rapid laboratory systems attack the same problem from the central-lab side.

This report follows the chain link by link. It explains the PA-100 technology and the Longitude Prize's evaluation logic, reviews the HTA evidence generation underway, and dissects the community-prescribing economics that will determine adoption. It maps the regulatory pathways - IVDR, MHRA, FDA, PMDA - and the competitive landscape from bioMerieux and BD to Q-linea and the molecular alternatives. A dedicated chapter asks the Japan question directly: whether Sysmex brings PA-100 through PMDA into a clinic-dense primary care system with strong stewardship ambitions and no established payment shelf for point-of-care AST.

The report serves IVD companies with AST portfolios, AMR-focused investors, health-system procurement analysts, and policy researchers tracking stewardship technology.

Scope and Coverage: The report covers rapid phenotypic antimicrobial susceptibility testing at the point of care following the Longitude Prize: technology, evidence generation, health economics, regulation, competition, and the Japan opportunity. Comparative coverage includes the UK, EU, US, and Japan.

Report Highlights:

PA-100 technology anatomy and the Longitude Prize evaluation framework
HTA evidence requirements and the studies designed to meet them
Community prescribing economics for urinary tract infection in the UK and Japan
Regulatory pathways: IVDR reclassification, MHRA, FDA, and PMDA
Competitive landscape: laboratory AST incumbents and rapid-system challengers
The Japan entry question and primary-care channel analysis

Product Code: JPH-052

Table of Content

1. Executive Summary

2. Point-of-Care Antimicrobial Susceptibility Testing After the Longitude Prize: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

Sysmex (JP) - PA-100 rapid phenotypic AST via Astrego; Longitude Prize winner with a Japan PMDA decision pending. bioMerieux (FR) - VITEK 2 AST standard, VITEK REVEAL rapid AST from the Specific Diagnostics acquisition, and BIOFIRE syndromic panels. Becton Dickinson (US) - Phoenix AST system and BD Kiestra laboratory automation. Q-linea (SE) - ASTar system delivering rapid AST from positive blood culture. Selux Diagnostics (US) - NGS-plus-phenotyping rapid AST platform with FDA clearances. Accelerate Diagnostics (US) - Accelerate Pheno rapid identification and AST from positive blood cultures. Roche (CH) - point-of-care expansion via LumiraDx platform assets alongside central-lab diagnostics. Thermo Fisher Scientific (US) - Sensititre AST plates and antimicrobial testing consumables. Bruker (DE) - MALDI Biotyper organism identification feeding AST workflows. Gradientech (SE) - QuickMIC rapid AST for sepsis blood cultures. Specific Diagnostics (US) - REVEAL rapid AST technology acquired by bioMerieux (2022). Autobio Diagnostics (CN) - microbiology and AST instruments in the China market.

Product Code: JPH-052

List of Tables

Table 1. Antimicrobial resistance burden: framing and measurement approaches
Table 2. Empiric prescribing practice in urinary tract infection
Table 3. Antibiotic stewardship policy in Japan
Table 4. Japan national AMR action plan: diagnostics components
Table 5. UTI care pathways in primary care
Table 6. Conventional culture-and-sensitivity workflow and turnaround structure
Table 7. Prescribing behavior research in Japan and the UK
Table 8. PA-100 platform: microfluidic design and measurement principle
Table 9. PA-100 UTI panel composition
Table 10. Longitude Prize competition design and evaluation criteria
Table 11. PA-100 clinical evidence program
Table 12. Sysmex commercialization plan for PA-100
Table 13. UK registration progress and NHS pilot status
Table 14. Japan PMDA pathway for PA-100
Table 15. HTA evidence requirements for rapid AST
Table 16. NICE evaluation framework for diagnostics
Table 17. NHS community prescribing economics for UTI
Table 18. Cost structure of conventional AST pathways
Table 19. Budget impact framework for point-of-care AST
Table 20. Outcome evidence designs: antibiotic use and clinical endpoints
Table 21. Japan HTA application to diagnostics
Table 22. Reimbursement scenarios for point-of-care AST in Japan
Table 23. IVDR classification of AST devices
Table 24. IVDR transition deadlines and manufacturer responses
Table 25. MHRA registration process
Table 26. FDA pathways for rapid AST
Table 27. PMDA review requirements for phenotypic AST
Table 28. NHI price formation for novel diagnostic categories
Table 29. Laboratory versus near-patient testing regulatory distinction
Table 30. Quality assurance requirements for point-of-care AST
Table 31. Data connectivity and reporting requirements
Table 32. bioMerieux VITEK 2 installed base position
Table 33. bioMerieux VITEK REVEAL rapid AST from Specific Diagnostics
Table 34. BD Phoenix and Kiestra laboratory ecosystem
Table 35. Q-linea ASTar: rapid AST from positive blood cultures
Table 36. Selux next-generation phenotyping system
Table 37. Accelerate Diagnostics Pheno system
Table 38. Lateral-flow and non-microfluidic rapid AST approaches
Table 39. Molecular resistance marker tests versus phenotypic AST
Table 40. Competitive positioning framework by care setting
Table 41. Japan primary care structure and clinic density
Table 42. Urology and women's health clinic channels in Japan
Table 43. Reference laboratory concentration and send-out culture
Table 44. Adoption barrier map for point-of-care AST in Japan
Table 45. Pilot program design options for Japan
Table 46. Stewardship program integration models
Table 47. AMR investor landscape and funding activity
Table 48. Policy watchlist for AMR diagnostics
Table 49. Adoption scenario framework
Table 50. Report methodology and evidence sources

List of Figures

Figure 1. AMR burden framing schematic
Figure 2. Empiric prescribing pathway for UTI
Figure 3. Japan stewardship policy structure
Figure 4. AMR action plan diagnostics component map
Figure 5. UTI care pathway flow in primary care
Figure 6. Conventional AST workflow and timeline
Figure 7. Prescribing behavior evidence map
Figure 8. PA-100 microfluidic measurement schematic
Figure 9. PA-100 panel composition map
Figure 10. Longitude Prize evaluation framework
Figure 11. PA-100 evidence program structure
Figure 12. Sysmex commercialization roadmap schematic
Figure 13. UK registration and pilot status map
Figure 14. PMDA pathway schematic for PA-100
Figure 15. HTA evidence requirement hierarchy
Figure 16. NICE diagnostics evaluation flow
Figure 17. NHS UTI prescribing economics structure
Figure 18. Conventional AST cost structure schematic
Figure 19. Budget impact model structure for point-of-care AST
Figure 20. Outcome study design taxonomy
Figure 21. Japan HTA application map for diagnostics
Figure 22. Reimbursement scenario map for Japan
Figure 23. IVDR classification decision tree for AST
Figure 24. IVDR transition timeline and responses
Figure 25. MHRA registration flow
Figure 26. FDA rapid AST pathway map
Figure 27. PMDA phenotypic AST review requirement map
Figure 28. NHI price formation flow for novel diagnostics
Figure 29. Laboratory versus near-patient regulatory map
Figure 30. Quality assurance framework for point-of-care AST
Figure 31. Connectivity and reporting architecture
Figure 32. VITEK 2 installed base structure
Figure 33. VITEK REVEAL workflow
Figure 34. BD Phoenix-Kiestra ecosystem map
Figure 35. Q-linea ASTar workflow
Figure 36. Selux system schematic
Figure 37. Accelerate Pheno workflow
Figure 38. Non-microfluidic rapid AST approach map
Figure 39. Molecular versus phenotypic AST comparison framework
Figure 40. Competitive positioning matrix by setting
Figure 41. Japan primary care structure map
Figure 42. Urology and women's health channel map
Figure 43. Reference lab concentration map
Figure 44. Adoption barrier map for Japan
Figure 45. Pilot design option taxonomy
Figure 46. Stewardship integration model map
Figure 47. AMR investor landscape map
Figure 48. Policy watchlist timeline
Figure 49. Adoption scenario tree
Figure 50. Report methodology schematic

Point-of-Care Antimicrobial Susceptibility Testing After the Longitude Prize | Diagnostics Market Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. Point-of-Care Antimicrobial Susceptibility Testing After the Longitude Prize: Technology and Test Landscape

3. Clinical Evidence and Guideline Context

4. Regulatory Status: PMDA, FDA, IVDR, and NMPA Pathways

5. Reimbursement and Price Formation with a Focus on Japan

6. Adoption, Channels, and Screening Infrastructure in Japan

7. Competitive Landscape: Companies and Platforms

8. Opportunities and Barriers for Market Participants

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures